MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$7,092K
Free Cash flow
$2,446K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Accounts receivable
Proceeds from issuance of common...
Non-cash interest expense
Others
Negative Cash Flow Breakdown
Repayment of wcf liability
Accrued expense and other curren...
Purchase of ipr&d asset
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
-8,908
-9,054
-12,244
540
Depreciation
585
328
321
318
Amortization of intangible asset
-
-
0
0
Impairment of fixed assets
64
-
-
-
Bad debt expense
-1
199
94
426
Change in fair value of warrant liability
-566
-456
-2,262
-1,464
Non-cash royalty revenue related to sale of future royalties
402
341
443
462
Non-cash research and development expense
-
-
0
-
Non-cash interest expense
2,807
4,577
4,752
4,619
Non-cash operating lease expense
-1,224
-1,198
-1,174
-1,150
Non-cash loss on extinguishment of debt
-
-
0
0
Non-cash write-off on termination of lease
-
-
0
-
Charge for purchase of ipr&d asset
-
-
12,807
-
Write-down of inventory
1,727
3,216
1,860
530
Change in excess inventory purchase commitments
-
-
0
0
Gain on the sale of property and equipment
0
0
0
0
Change in fair value of embedded debt derivative
-
-
0
-
Stock-based compensation expense
3,226
3,668
3,199
3,221
Accounts receivable
-9,031
15,704
-19,098
-6,160
Inventory
655
2,540
17,418
-6,899
Prepaid expenses and other current assets
2,172
-170
-1,560
-2,501
Other long-term assets
-39
749
2,763
-38
Accounts payable
2,602
-7,792
10,419
-8,828
Accrued expense and other current liabilities
-5,441
2,035
13,928
15,824
Operating lease liabilities
-1,189
-1,422
-1,388
-1,364
Deferred revenue
1,673
1,815
-1,200
-1,651
Other long-term liabilities
-119
-355
-365
-352
Net cash provided by (used in) operating activities
3,525
-21,207
31,129
28,105
Purchases of equipment
1,079
62
70
77
Proceeds from the sale of property and equipment
0
0
0
0
Purchase of ipr&d asset
3,000
-
7,807
-
Net cash provided by (used in) investing activities
-4,079
-62
-7,877
-77
Proceeds from the issuance of debt
0
0
0
0
Payments of issuance costs related to blackrock credit agreement
0
0
0
0
Proceeds from issuance of common stock, net of issuance costs
3,240
0
0
0
Proceeds from issuance of stock under employee stock purchase plan
0
131
0
152
Proceeds from the exercise of stock options
85
20
63
961
Repayment of wcf liability
8,362
492
1,146
-
Repayment of liability related to settlement royalties
1,501
585
3,765
-
Repayment of term debt
0
0
0
0
Net cash provided by (used in) financing activities
-6,538
-926
-4,848
1,113
Increase (decrease) in cash, cash equivalents and restricted cash
-7,092
-22,195
18,404
29,141
Cash, cash equivalents and restricted cash beginning of period
164,348
186,543
168,139
53,550
Cash, cash equivalents and restricted cash end of period
157,256
164,348
186,543
168,139
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Accounts receivable
-$9,031K
(-122.92%↓ Y/Y)
Stock-based compensation
expense
$3,226K
(-33.66%↓ Y/Y)
Non-cash interest
expense
$2,807K
(-77.43%↓ Y/Y)
Accounts payable
$2,602K
(74.51%↑ Y/Y)
Write-down of inventory
$1,727K
(1401.74%↑ Y/Y)
Deferred revenue
$1,673K
(-69.76%↓ Y/Y)
Non-cash operating lease
expense
-$1,224K
(45.14%↑ Y/Y)
Depreciation
$585K
(-7.14%↓ Y/Y)
Impairment of fixed assets
$64K
Other long-term
assets
-$39K
(62.14%↑ Y/Y)
Net cash provided by
(used in) operating...
$3,525K
(-59.75%↓ Y/Y)
Canceled cashflow
$19,453K
Increase (decrease) in
cash, cash...
-$7,092K
(-108.30%↓ Y/Y)
Canceled cashflow
$3,525K
Proceeds from issuance of
common stock, net of...
$3,240K
(-95.12%↓ Y/Y)
Proceeds from the
exercise of stock options
$85K
(-87.12%↓ Y/Y)
Net income (loss)
-$8,908K
(-240.08%↓ Y/Y)
Accrued expense and
other current...
-$5,441K
(-128.98%↓ Y/Y)
Prepaid expenses and
other current assets
$2,172K
(161.74%↑ Y/Y)
Operating lease
liabilities
-$1,189K
(55.08%↑ Y/Y)
Inventory
$655K
(-94.80%↓ Y/Y)
Change in fair value of
warrant liability
-$566K
(-108.29%↓ Y/Y)
Non-cash royalty revenue
related to sale of future...
$402K
(-53.42%↓ Y/Y)
Other long-term
liabilities
-$119K
(-119.67%↓ Y/Y)
Bad debt expense
-$1K
(-100.10%↓ Y/Y)
Net cash provided by
(used in) financing...
-$6,538K
(-108.53%↓ Y/Y)
Net cash provided by
(used in) investing...
-$4,079K
(-14667.86%↓ Y/Y)
Canceled cashflow
$3,325K
Repayment of wcf liability
$8,362K
Purchase of ipr&d asset
$3,000K
Purchases of equipment
$1,079K
(649.31%↑ Y/Y)
Repayment of liability
related to settlement...
$1,501K
Buy us a coffee
Akebia Therapeutics, Inc. (AKBA)
Akebia Therapeutics, Inc. (AKBA)